Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus

Sanwa Kagaku Kenkyusho Co., Ltd.

Overview

The purpose of this study is to evaluate the clinical efficacy and safety of SK-0403 in patients with Type2 Diabetes Mellitus

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Conditions

Type 2 Diabetes Mellitus

Interventions

SK-0403DRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 74 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Treatment-naive subjects diagnosed with type 2 diabetes mellitus * Stable diet program for at least 8 weeks * Criteria for HbA1c are met Exclusion Criteria: * Type 1 diabetes * Patients treated with other antidiabetic drugs or Insulin

Locations (10)

Unnamed facility

Fukuoka, Japan

Unnamed facility

Gifu, Japan

Unnamed facility

Gunma, Japan

Unnamed facility

Hokkaido, Japan

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.